Pulmatrix Reports Material Agreement, Potential Financial & Officer Changes

Ticker: PULM · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1574235

Complexity: simple

Sentiment: mixed

Topics: material-agreement, corporate-governance, financial-condition

TL;DR

**Pulmatrix just dropped an 8-K hinting at big corporate moves, watch for details!**

AI Summary

Pulmatrix, Inc. filed an 8-K on January 8, 2024, reporting an event that occurred on January 6, 2024. The filing indicates significant corporate activity, including an entry into a material definitive agreement, potential changes in financial condition or operations, and possibly changes in executive compensation or officer appointments. This matters to investors because such events can signal strategic shifts, financial health changes, or leadership transitions, all of which can impact the company's future performance and stock value.

Why It Matters

This filing signals potential strategic shifts and operational changes at Pulmatrix, Inc., which could significantly influence its financial outlook and stock performance.

Risk Assessment

Risk Level: medium — The filing indicates significant corporate events without specific details, creating uncertainty about their potential positive or negative impact.

Analyst Insight

Investors should closely monitor subsequent filings or press releases from Pulmatrix, Inc. for specific details on the 'Material Definitive Agreement' and any changes to 'Results of Operations and Financial Condition' or 'Compensatory Arrangements of Certain Officers' to understand the full impact on the company's future.

Key Players & Entities

FAQ

What was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on January 6, 2024, as stated under 'Date of Report (Date of earliest event reported): January 6, 2024'.

What specific items of information are included in this 8-K filing?

This 8-K filing includes information regarding 'Entry into a Material Definitive Agreement', 'Results of Operations and Financial Condition', 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers', 'Regulation FD Disclosure', 'Other Events', and 'Financial Statements and Exhibits'.

What is the business address of Pulmatrix, Inc. as listed in the filing?

The business address of Pulmatrix, Inc. is 36 Crosby Drive, Suite 100, Bedford, MA 01730, as specified in the filing.

What is the Commission File Number for Pulmatrix, Inc.?

The Commission File Number for Pulmatrix, Inc. is 001-36199, as indicated in the filing.

What is the telephone number for Pulmatrix, Inc. according to the filing?

The telephone number for Pulmatrix, Inc. is (781) 357-2333, as listed in the filing.

Filing Stats: 1,716 words · 7 min read · ~6 pages · Grade level 13 · Accepted 2024-01-08 09:00:24

Key Financial Figures

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. The Company also intends, from time to time, to present and/or distribute to the investment community and utilize at various industry and other conferences a slide presentation, which is attached hereto as Exhibit 99.2. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.2. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.2, being furnished pursuant to Item 7.01, shall not be deemed to be "filed" for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. Item 8.01 Other Events On January 8, 2024, the Company issued the Press Release, which is attached hereto as Exhibit 99.1 and incorporated herein by reference (excluding the portions of Exhibit 99.1 that are furnished and not deemed "filed" pursuant to Item 2.02 of this Current Report on Form 8-K). Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1* Third Amendment to Development and Commercialization Agreement, dated January 6, 2024, by and between the Company, Pulmatrix Operating Company, Inc., and Cipla Technologies LLC 10.2 Letter Agreement, dated January 6, 2024, by and between Teofilo Raad and the Company 99.1** Press Release, dated January 8, 2024 99.2 Investor Presentation (furnished herewith pursuant to Item 7.01) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Certain of the schedules (and similar attachments) to this exhibit have been omitted in accordance with Item 601(a)(5) of Regulation S-K under the Securities Act because they do not contain information mat

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PULMATRIX, INC. Date: January 8, 2024 By: /s/ Teofilo Raad Teofilo Raad Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing